Inhibrx Biosciences Inc (INBX)
14.93
-0.52
(-3.37%)
USD |
NASDAQ |
Nov 14, 12:50
Inhibrx Biosciences Total Liabilities (Quarterly): 39.05M for June 30, 2024
Total Liabilities (Quarterly) Chart
Historical Total Liabilities (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2024 | 39.05M |
| Date | Value |
|---|---|
| March 31, 2024 | 38.99M |
Total Liabilities Definition
Liabilities are a main portion of the balance sheet of a company that measure outstanding payables/obligations. A few examples of liabilties of a company include accounts payable, current debt, and capital lease obligations. From an accounting perspective, the balance sheet equation is Liabilties = Assets - Shareholder's Equity.
Total Liabilities (Quarterly) Range, Past 5 Years
38.99M
Minimum
Mar 2024
39.05M
Maximum
Jun 2024
39.02M
Average
39.02M
Median
Total Liabilities (Quarterly) Benchmarks
| CEL-SCI Corp | 15.60M |
| AIM ImmunoTech Inc | 9.613M |
| IGC Pharma Inc | 2.714M |
| NovaBay Pharmaceuticals Inc | 4.542M |
| Protalix BioTherapeutics Inc | 62.96M |
Total Liabilities (Quarterly) Related Metrics
| Total Assets (Quarterly) | 258.42M |
| Shareholders Equity (Quarterly) | 219.37M |
| Current Ratio | 6.198 |